General Information of Drug (ID: DM8WBAH)

Drug Name
DEXMETHYLPHENIDATE HYDROCHLORIDE
Synonyms
Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 269.77
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 4
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 3
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3-6 h [2]
Bioavailability
The bioavailability of drug is 32% [2]
Clearance
The renal clearance of drug is 0.005 L/h/kg []
Elimination
Dexmethylphenidate is mainly eliminated renally, and 90% of the dose is collected in the urine and 3.3% is collected from feces [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.2 hours [4]
Metabolism
The drug is metabolized via the carboxylesterase 1A1 in the liver [3]
Vd
The volume of distribution (Vd) of drug is 2.65 L/kg [3]
Chemical Identifiers
Formula
C14H20ClNO2
IUPAC Name
methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate;hydrochloride
Canonical SMILES
COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2.Cl
InChI
InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
InChIKey
JUMYIBMBTDDLNG-OJERSXHUSA-N
Cross-matching ID
PubChem CID
154100
CAS Number
19262-68-1
TTD ID
D02QCD
VARIDT ID
DR00844

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Attention deficit hyperactivity disorder
ICD Disease Classification 6A05.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine transporter (DAT) DTT SLC6A3 1.08E-03 -3.08 -1.99
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Zepatier FDA label
3 Latini R, Tognoni G, Kates RE: Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002.
4 Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol. 2000 Oct;40(10):1141-9.
5 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.